Navigation Links
Par Pharmaceutical Reports First Quarter 2008 Results
Date:5/8/2008

trategy, and I am pleased with our progress thus far. Par should be measured in large part by the achievement of certain accomplishments and milestones that position the Company for growth in 2009 and beyond."

In January, Strativa acquired the U.S. commercialization rights to Alfacell Corporation's Phase III product, ONCONASE, for an initial payment of $5 million. Results from the Phase IIIb clinical trial will be reported by mid-year. Subject to a complete review of the study results and discussions with the FDA, it is anticipated that an NDA could be filed as early as year-end 2008.

In March, Par commenced bioequivalence studies for Zensana(TM) (ondansetron) oral spray. Subject to favorable results and discussions with the FDA, it is expected that Strativa could file an NDA around the end of 2008.

In April, Strativa announced that its development partner, BioAlliance Pharma, reported positive preliminary, top-line results from a Phase III study of Loramyc(R) (miconazole Lauriad(R)). Subject to a complete review of the study results and discussions with the FDA, it is anticipated that an NDA could be filed by year-end 2008.

On May 7, 2008, Par announced that it amended its agreement with Spectrum Pharmaceuticals and paid $20 million in cash to increase its share of profits from the generic versions of GlaxoSmithKline's Imitrex(R) Injection, which will be immediately accretive to 2008 earnings. As a result of the agreement, Par's profit share shall increase from 38% to 95% from the commercialization of sumatriptan injection. Par will be permitted to sell generic versions of certain sumatriptan injection products with an expected launch date no later than November 2008. According to IMS Health, annual U.S. sales of Imitrex(R) are approximately $220 million.

2008 Financial Guidance

The Company's projections are based on its results for the first three months of 2008, as well as management's estimates regarding the impact of pr
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Vion Pharmaceuticals to Appeal Nasdaq Delisting
2. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
3. AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company
4. Par Pharmaceutical Acquires Spectrum Pharmaceuticals Interest In Sumatriptan Injection
5. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
6. Cadient Group Continues Winning Streak; Receives Multiple Honors at 2008 Pharmaceutical Advertising and Marketing Excellence Awards
7. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
8. Par Pharmaceutical to Host First Quarter 2008 Earnings Conference Call on May 9 at 9:00 AM
9. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
10. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
(Date:4/23/2014)... The internal surface area of the gastro-intestinal tract has ... square meters. Scientists at the Sahlgrenska Academy have used ... , "Actually, the inner surface of the gastro-intestinal tract ... says scientist Lars Fndriks. , The digestive tract, which ... through the intestines, has a length of about 5 ...
(Date:4/23/2014)... In science, "simple and accessible detection methods that ... the resolution of a single cell inside that ... chemical engineer Chang Lu. , In the Royal ... Lu has announced that he and his coworkers ... subcellular location of a protein ( Chem. Sci. ...
(Date:4/23/2014)... Fruits and vegetables are often displayed in the ... are also plenty of high-sugar foods. A new ... food is portrayed in children,s TV programmes as ... viewing, dietary habits and weight status. , Steingerdur ... food in the popular Swedish children,s TV show ...
(Date:4/23/2014)... from the Cancer Science Institute of Singapore (CSI Singapore) ... cancer specific stem cell which causes gastric cancer. This ... for the treatment of this disease and other types ... Chan Shing Leng, Research Assistant Professor at CSI Singapore, ... of a cell surface protein, CD44v8-10, marks gastric cancer ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... TUESDAY, Aug. 23 (HealthDay News) -- The amount of fighting ... over the years, a new study suggests. Ohio State ... were followed from 1980 to 2000. Based on how often ... divided into low-, middle- and high-conflict marriages. There was ...
... University of Liverpool have found that children as young as ... before they have learned to speak in full sentences. ... aged two, sentences containing made-up verbs, such as ,the rabbit ... sentence with a cartoon picture. They found that even ...
... , TUESDAY, Aug. 23 (HealthDay News) -- Bullying may ... if they,re black and Hispanic teens who are high achievers, ... point averages (GPAs) of 9,590 students from 580 U.S. high ... grade 10. Compared to kids who were not bullied, ...
... The National Cancer Institute today announced that a ... The Broad Institute in Cambridge, Mass., has been selected ... dedicated to understanding the molecular basis of cancer . ... in the blood that are associated with genetic alterations ...
... Mich. Nearly 17 percent of nurses who work in ... or eyes to the toxic drugs they deliver, according to ... Center. The study surveyed 1,339 oncology nurses from one ... 84 percent of chemotherapy is delivered in outpatient settings, largely ...
... Aug. 22 (HealthDay News) -- A drive to further your ... search methods are the three key ingredients to helping today,s ... economy. That,s the take-home message of a new study ... American Sociological Association in Las Vegas. "Although structural factors ...
Cached Medicine News:Health News:Couples Who Don't Fight Much Aren't Likely to Start 2Health News:2-year-old children understand complex grammar 2Health News:Grades May Suffer When Teens Get Bullied 2Health News:Fred Hutchinson Cancer Research Center to co-lead 1 of 5 NCI-funded proteomics research centers 2Health News:17 percent of cancer nurses unintentionally exposed to chemotherapy, U-M study finds 2Health News:Study Shows Key Ways Young Adults Can Find, Keep a Job 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
Medicine Products: